USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA

An inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of Cipla Limited) located in Central Islip, Long Island, New York, USA, from 13th July, 2026 to 17th July, 2026 (EDT). The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection.

On conclusion of the inspection, the Company has received 1 (one) inspectional observation in Form 483. The Company will work closely with the USFDA and is committed to address this comprehensively within stipulated time.

Shares of Cipla Limited was last trading in BSE at Rs. 1418.40 as compared to the previous close of Rs. 1429.45. The total number of shares traded during the day was 29147 in over 4381 trades.

The stock hit an intraday high of Rs. 1442.50 and intraday low of 1404.40. The net turnover during the day was Rs. 41240397.00.

Source : Equity Bulls

Keywords

Cipla INE059A01026 Pharmaceuticals InvaGenPharmaceuticals ManufacturingFacility USFDA Inspection